

What's the Hype about Myasthenia Gravis?

presented by

Pushpa Narayanaswami, MD

9/25/2025 8:00:00 AM

Zoom & In Person (Contact Activity Coordinator or sponsoring department for more information)

Learning Objectives: *As a result of participating in this Live Activity, participants should be able to:*

- 1 summarize the pathophysiology of MG as it relates to new targeted therapies.*
- 2 evaluate the use of targeted therapies in clinical practice.*
- 3 demonstrate the role of conventional treatments in the era of targeted therapies.*

Accreditation Statement: In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement: Hartford Healthcare designates this Live Activity for 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with their participation.

Financial Disclosures:

- PUSHPA NARAYANASWAMI, MD : Advisor-Amgen, Inc.|Advisor-Alexion Pharmaceuticals|Advisor-Argenx|Consulting Fee-CVS Caremark|Advisor-Cartesian (Relationship has ended)|Advisor-Dianthus|Advisor-Immunovant|Consulting Fee-ImmuneAbs (Relationship has ended)|Advisor-EMD Serono|Advisor-Janssen (Any division)|Advisor-UCB|Consulting Fee-viridian (Relationship has ended)|Grant or research support-Alexion Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sanofi S.A. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Argenx|Membership on Advisory Committees or Review Panels, Board Membership, etc.-NMD pharma|Royalties or Patent Beneficiary-Springer Nature - 09/02/2025



